KEROS THERAPEUTICS IN

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

12 12 2022 10:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

22 11 2022 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

07 11 2022 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

03 11 2022 09:00:03 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

03 11 2022 07:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

12 9 2022 06:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

06 9 2022 08:00:02 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

04 8 2022 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

13 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

10 6 2022 06:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

18 5 2022 06:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

17 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

12 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports First Quarter 2022 Financial Results

05 5 2022 08:00:03 提供 Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

09 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 2 2022 08:00:00 提供 Nasdaq GlobeNewswire

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

31 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 12 2021 16:05:00 提供 Nasdaq GlobeNewswire